1. Home
  2. RVNC vs NCV Comparison

RVNC vs NCV Comparison

Compare RVNC & NCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RVNC
  • NCV
  • Stock Information
  • Founded
  • RVNC 1999
  • NCV 2003
  • Country
  • RVNC United States
  • NCV United States
  • Employees
  • RVNC N/A
  • NCV N/A
  • Industry
  • RVNC Biotechnology: Pharmaceutical Preparations
  • NCV Finance Companies
  • Sector
  • RVNC Health Care
  • NCV Finance
  • Exchange
  • RVNC Nasdaq
  • NCV Nasdaq
  • Market Cap
  • RVNC 546.4M
  • NCV 320.8M
  • IPO Year
  • RVNC 2014
  • NCV N/A
  • Fundamental
  • Price
  • RVNC $5.29
  • NCV $3.54
  • Analyst Decision
  • RVNC Buy
  • NCV
  • Analyst Count
  • RVNC 10
  • NCV 0
  • Target Price
  • RVNC $10.86
  • NCV N/A
  • AVG Volume (30 Days)
  • RVNC 1.3M
  • NCV 405.1K
  • Earning Date
  • RVNC 11-06-2024
  • NCV 01-01-0001
  • Dividend Yield
  • RVNC N/A
  • NCV 12.48%
  • EPS Growth
  • RVNC N/A
  • NCV N/A
  • EPS
  • RVNC N/A
  • NCV N/A
  • Revenue
  • RVNC $251,178,000.00
  • NCV N/A
  • Revenue This Year
  • RVNC $20.36
  • NCV N/A
  • Revenue Next Year
  • RVNC $31.66
  • NCV N/A
  • P/E Ratio
  • RVNC N/A
  • NCV N/A
  • Revenue Growth
  • RVNC 40.23
  • NCV N/A
  • 52 Week Low
  • RVNC $2.30
  • NCV $2.84
  • 52 Week High
  • RVNC $9.75
  • NCV $3.59
  • Technical
  • Relative Strength Index (RSI)
  • RVNC 44.50
  • NCV 53.82
  • Support Level
  • RVNC $5.10
  • NCV $3.51
  • Resistance Level
  • RVNC $5.43
  • NCV $3.58
  • Average True Range (ATR)
  • RVNC 0.17
  • NCV 0.05
  • MACD
  • RVNC 0.02
  • NCV -0.00
  • Stochastic Oscillator
  • RVNC 66.67
  • NCV 52.42

About RVNC Revance Therapeutics Inc.

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.

About NCV Virtus Convertible & Income Fund of Beneficial Interest

Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.

Share on Social Networks: